Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Biocryst Pharma Inc (BCRX)
Biocryst Pharma Inc (BCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,581,104
  • Shares Outstanding, K 188,451
  • Annual Sales, $ 270,830 K
  • Annual Income, $ -247,120 K
  • 60-Month Beta 2.03
  • Price/Sales 5.96
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BCRX with:

Options Overview Details

View History
  • Implied Volatility 54.09% ( +54.09%)
  • Historical Volatility 66.94%
  • IV Percentile 11%
  • IV Rank 14.72%
  • IV High 96.88% on 05/11/22
  • IV Low 46.71% on 03/20/23
  • Put/Call Vol Ratio 0.75
  • Today's Volume 695
  • Volume Avg (30-Day) 1,421
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 69,942
  • Open Int (30-Day) 74,149

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.30
  • Number of Estimates 6
  • High Estimate -0.16
  • Low Estimate -0.39
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.82 +7.86%
on 03/10/23
8.99 -6.17%
on 03/01/23
-0.41 (-4.69%)
since 02/28/23
3-Month
7.82 +7.86%
on 03/10/23
12.07 -30.14%
on 01/06/23
-2.38 (-22.04%)
since 12/28/22
52-Week
7.61 +10.84%
on 05/12/22
18.00 -53.14%
on 04/07/22
-7.77 (-47.96%)
since 03/28/22

Most Recent Stories

More News
Why Shares of BioCryst Pharmaceuticals Jumped Today

A day after the stock plummeted, it bounced back.

BCRX : 8.35 (-0.48%)
Why BioCryst Pharmaceuticals Stock Is Sinking Today

Investors didn't like the drugmaker's Q4 update.

BCRX : 8.35 (-0.48%)
BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript

BCRX earnings call for the period ending December 31, 2022.

BCRX : 8.35 (-0.48%)
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -100% and 6.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

BCRX : 8.35 (-0.48%)
ACRS : 8.11 (-2.64%)
BioCryst: Q4 Earnings Snapshot

BioCryst: Q4 Earnings Snapshot

BCRX : 8.35 (-0.48%)
Why Earnings Season Could Be Great for BioCryst (BCRX)

BioCryst (BCRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BCRX : 8.35 (-0.48%)
Earnings Preview: Ionis Pharmaceuticals (IONS) Q4 Earnings Expected to Decline

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IONS : 35.61 (+2.06%)
BCRX : 8.35 (-0.48%)
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BCRX : 8.35 (-0.48%)
IRWD : 10.53 (+1.06%)
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

NBIX : 101.25 (+2.06%)
BCRX : 8.35 (-0.48%)
Wall Street Analysts Predict a 48% Upside in BioCryst (BCRX): Here's What You Should Know

The mean of analysts' price targets for BioCryst (BCRX) points to a 47.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

BCRX : 8.35 (-0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential...

See More

Key Turning Points

3rd Resistance Point 9.02
2nd Resistance Point 8.86
1st Resistance Point 8.63
Last Price 8.35
1st Support Level 8.23
2nd Support Level 8.07
3rd Support Level 7.84

See More

52-Week High 18.00
Fibonacci 61.8% 14.03
Fibonacci 50% 12.81
Fibonacci 38.2% 11.58
Last Price 8.35
52-Week Low 7.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar